Q-Line Biotech Limited, a prominent and research-driven player in India's medical diagnostics and healthcare solutions industry, has officially rolled out its Initial Public Offering (IPO).
This article breaks down the key details of the IPO, including its financials, objectives, and timeline.
IPO Details & Timeline
| Bidding Period | May 21, 2026 – May 25, 2026 |
| Price Band | ₹326 – ₹343per equity share |
| Base Lot Size | 400 Shares |
| Minimum Retail Application | 2 Lots (800 Shares) |
| Minimum Retail Investment | ₹2,74,400 (at the upper price band) |
| Listing Platform | NSE SME |
| Total Issue Size | ₹214.48 Cr (62,53,200 Equity Shares) |
| Issue Type | 100% Fresh Issue |
About the Company
Originally incorporated as POCT Services Private Limited in 2010, Q-Line Biotech Limited has built an established, 12-year track record as an integrated manufacturer and developer within the fast-growing domestic In-Vitro Diagnostics (IVD) vertical.
Business Model: The company operates a high-volume B2B distribution model, directly catering to diagnostic laboratory networks, hospital systems, medical research colleges, and retail healthcare facilities across the country.
Product Catalog: Q-Line focuses on a highly diversified product footprint consisting of diagnostic reagents, biochemical testing kits, consumable assay products, and specialized path-lab analyzers. Its segments span Clinical Chemistry, Hematology, Molecular Diagnostics, and Immunodiagnostics.
Manufacturing & Infrastructure: Under the Government of India’s “Make in India” framework, the company runs four state-of-the-art production plants (three located in Lucknow, Uttar Pradesh, and one in Delhi) along with a dedicated R&D hub consisting of 19 specialized scientists.
Financial Snapshot
Here is a summary of Q-line Biotech Limited's financial performance over the last three financial years.
(All financial figures are in ₹ Crores)
| Particulars | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue from Operations | ₹322.58 | ₹206.45 | ₹184.81 |
| Profit After Tax (PAT) | ₹28.13 | ₹34.44 | ₹32.10 |
Key Financial Highlights:
Top-Line Trajectory: Core operating revenue expanded from ₹182.74 Crores in FY23 to ₹313.78 Crores in FY25, representing an absolute growth of 71.7% over the two-year period.
Earnings Volatility: While EBITDA scaled alongside revenues, Profit After Tax (PAT) dropped to ₹28.13 Crores in FY25 from ₹34.44 Crores in FY24. This contraction was driven by non-operational exceptional items and specific financial adjustments noted in the restated logs.
Current Run-Rate: The data for the first 9 months of the subsequent period indicates an upward correction in profitability, registering a PAT of ₹38.69 Crores.
Objects of the Issue
The company will receive no proceeds from an Offer for Sale (OFS) because the transaction consists entirely of fresh shares. The net proceeds of ₹214.48 Crores are structurally allocated as follows:
Working Capital Requirements (~₹93.50 Crore): Allocated to manage internal inventory holding cycles, fund trade receivables timelines, and support ongoing production cycles for incoming product lines.
Debt De-leveraging (~₹90.00 Crore): Assigned to execute the full or partial prepayment of high-interest outstanding bank borrowings and short-term debt, aimed at lowering interest expenses and improving net cash margins.
General Corporate Purposes: The remaining capital balance will fund routine administrative costs, business development expenses, and legal or management costs associated with conducting the public offer.
Disclaimer: This article is for informational purposes only and should not be considered investment advice. Investors should conduct their own due diligence and consult with a financial advisor before making any investment decisions.
.png)
.png)
